SitemapContact Us
닫기
Search
Advanced Search +
닫기
Quick links
Most Cited Most Read Ahead of Print Archives Go to E-submission

Review Article

Split Viewer

Blood Res 2022; 57(S1):

Published online April 30, 2022

https://doi.org/10.5045/br.2022.2022037

© The Korean Society of Hematology

Basic immunohistochemistry for lymphoma diagnosis

Junhun Cho

Author Info. +

Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence to : Junhun Cho, M.D.
Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-Gu, Seoul 06351, Korea
E-mail: jununius@naver.com

Received: February 6, 2022; Revised: March 10, 2022; Accepted: March 15, 2022

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Go to

Immunohistochemistry is a technique that uses antigen-antibody interactions to detect specific proteins in cells. This technique has several essential applications in lymphoma diagnosis, including identifying the cell lineage and phase of maturation, detecting specific genetic alterations, visualizing the degree of cell proliferation, and identifying therapeutic targets. CD3 is a pan T-cell marker expressed on most of the mature T/NK-cell lymphomas, except for anaplastic large cell lymphoma, whereas CD20 is a pan B-cell marker that is expressed on most of the mature B-cell lymphomas. CD79a may be a good alternative to CD20, compensating for its loss owing to the plasmocytic differentiation of tumor cells or history of rituximab administration. CD56, a neuroendocrine marker, is used as an NK cell marker in lymphoma diagnosis. Characteristic translocations occurring in follicular lymphoma (BCL2) and mantle cell lymphoma (CCND1) can be detected by the overexpression of Bcl-2 and cyclin D-1 in immunohistochemistry, respectively. Ki-67 reflects the degree of tumor cell proliferation by indicating cells in cell cycle phases other than G0. With the development of immunotherapy, several antibodies against markers such as programmed death-ligand 1 (PD-L1), CD19, and CD30 have been used as biomarkers to identify therapeutic targets. It is critical to properly fix the specimens to obtain accurate immunohistochemical results. Therefore, all processes, from tissue collection to the final pathological diagnosis, must be performed appropriately for accurate lymphoma diagnosis.

Keywords Lymphoma, Immunohistochemistry, In situ hybridization

Article

Review Article

Blood Res 2022; 57(S1): S55-S61

Published online April 30, 2022 https://doi.org/10.5045/br.2022.2022037

Copyright © The Korean Society of Hematology.

Basic immunohistochemistry for lymphoma diagnosis

Junhun Cho

Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence to:Junhun Cho, M.D.
Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-Gu, Seoul 06351, Korea
E-mail: jununius@naver.com

Received: February 6, 2022; Revised: March 10, 2022; Accepted: March 15, 2022

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Immunohistochemistry is a technique that uses antigen-antibody interactions to detect specific proteins in cells. This technique has several essential applications in lymphoma diagnosis, including identifying the cell lineage and phase of maturation, detecting specific genetic alterations, visualizing the degree of cell proliferation, and identifying therapeutic targets. CD3 is a pan T-cell marker expressed on most of the mature T/NK-cell lymphomas, except for anaplastic large cell lymphoma, whereas CD20 is a pan B-cell marker that is expressed on most of the mature B-cell lymphomas. CD79a may be a good alternative to CD20, compensating for its loss owing to the plasmocytic differentiation of tumor cells or history of rituximab administration. CD56, a neuroendocrine marker, is used as an NK cell marker in lymphoma diagnosis. Characteristic translocations occurring in follicular lymphoma (BCL2) and mantle cell lymphoma (CCND1) can be detected by the overexpression of Bcl-2 and cyclin D-1 in immunohistochemistry, respectively. Ki-67 reflects the degree of tumor cell proliferation by indicating cells in cell cycle phases other than G0. With the development of immunotherapy, several antibodies against markers such as programmed death-ligand 1 (PD-L1), CD19, and CD30 have been used as biomarkers to identify therapeutic targets. It is critical to properly fix the specimens to obtain accurate immunohistochemical results. Therefore, all processes, from tissue collection to the final pathological diagnosis, must be performed appropriately for accurate lymphoma diagnosis.

Keywords: Lymphoma, Immunohistochemistry, In situ hybridization

Fig 1.

Download
Figure 1.Representative immuno-histochemical staining images of various type of diffuse large B-cell lymphomas.
Abbreviations: ABC, activated B-cell type; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell type; EBV DLBCL, EBV-positive diffuse large B-cell lymphoma.
Blood Research 2022; 57: S55-S61https://doi.org/10.5045/br.2022.2022037

Fig 2.

Download
Figure 2.Representative images of immunohistochemical staining of small/low grade B-cell lymphomas. Tumor cells are positive for CD10 and Bcl-2 in follicular lymphoma, positive for CD5 and CD23 in chronic lymphocytic leukemia/small lymphocytic lymphoma, positive for cyclin D-1 and SOX11 in mantle cell lymphoma.
Abbreviation: CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma.
Blood Research 2022; 57: S55-S61https://doi.org/10.5045/br.2022.2022037

Fig 3.

Download
Figure 3.Representative images of immunohistochemical staining of T/NK-cell lymphomas. In ALK-positive anaplastic large cell lymphoma, tumor cells are negative for CD3, and positive for CD30 and ALK. In angioimmunoblastic T-cell lymphoma, CD3 and CD20 shows mixed pattern of T- and B-cells. CD21 stain shows expanded follicular dendritic cell meshwork. EBV ISH is positive in scattered large B-cells. In extranodal NK/T-cell lymphoma, EBV positive cells are positive for CD3 and negative for CD79a in double stains.
Abbreviations: AITL, angioimmuno-blastic T-cell lymphoma; ALCL, ana-plastic large cell lymphoma; ENKTL, extranodal NK/T-cell lymphoma.
Blood Research 2022; 57: S55-S61https://doi.org/10.5045/br.2022.2022037

Fig 4.

Download
Figure 4.Representative images of immunohistochemical staining of precursor lymphomas. In T-lympho-blastic leukemia/lymphoma, tumor cells are positive for CD3, CD99 and TdT. In B-lymphoblastic leukemia/ lymphoma, tumor cells are negative for CD20, positive for CD79a and TdT.
Blood Research 2022; 57: S55-S61https://doi.org/10.5045/br.2022.2022037

Fig 5.

Download
Figure 5.Representative immunohistochemical staining images of Hodgkin lymphomas. In classic Hodgkin lymphoma, tumor cells are positive for CD30 and CD15. CD20 is negative and PAX5 is weak positive in large tumor cells. In nodular lymphocyte predominant Hodgkin lymphoma, tumor cells are positive for CD20 and Oct-2. CD30 is negative in tumor cells. CD3 stain shows peritumoral rosette-like T-cells.
Abbreviation: NLPHL, nodular lymphocyte predominant Hodgkin lymphoma.
Blood Research 2022; 57: S55-S61https://doi.org/10.5045/br.2022.2022037
Blood Res
Volume 59 2024
Current Issue Archives

Stats or Metrics

Share this article on

  • line

Related articles in BR

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download